

CURRICULUM VITAE di Paolo Milani**Informazioni personali****Esperienza professionale**

Medico specializzando presso la Clinica Medica 2 ed il Centro per lo Studio e la Cura delle Amiloidosi Sistemiche della S.C. L.S.R. Area Biotecnologie – Policlinico San Matteo, Pavia (2011-2016).
Research Fellow, Hematology Department, Mayo Clinic, Rochester, MN, USA (da aprile 2015 ad aprile 2016).

Percorso di studi

Laurea in Medicina e Chirurgia (110/110 e lode), Università di Pavia (2010).
Specializzazione in Medicina Interna (50/50 e lode), Università di Pavia (2016).
Dottorando di ricerca, corso di studi di Medicina Sperimentale, Università di Pavia (dall'ottobre 2015).

Società

Società Italiana per l'Amiloidosi, SIA (2010).
International Society of Amyloidosis, ISA (2010).
Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica, SiBioC (2011).
Società Italiana di Medicina Interna, SIMI (2012).
European Haematology Association, EHA (2014).
American Society of Hematology, ASH (2016).

Premi


International Society of Amyloidosis – Miglior poster – International Symposium on Amyloidosis, luglio 2016.
American Society of Hematology, Abstract Achievement Award, ASH meeting, dicembre 2015.
European Haematology Association – Travel Grant for the 20th EHA Congress, Vienna, giugno 2015.
Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica – Migliore presentazione poster al 46° Congresso Nazionale, Roma, Ottobre 2014.
Amyloidosis Foundation "Junior Researcher Travel Award" – ISA Symposium: 2012, 2014 e 2016.
International Society of Amyloidosis – "Best Oral Presentation for Young Researcher" – International Symposium on Amyloidosis 2012.
Società Italiana di Medicina Interna, premio Fondazione Aventis, (2012).
Collegio Ghislieri, Pavia – "Progetti in Biologia e Medicina" borsa di studio (2012).

Pubblicazioni su riviste scientifiche sottoposte a controllo redazionale

1. Gonsalves WI, Milani P, Derudas D, Buadi FK. The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncol. 2016 Aug 11. [Epub ahead of print].
2. Milani P, Rajkumar VS, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016 Aug 10. [Epub ahead of print]
3. Milani P, Palladini G, Merlini G. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. Scand J Clin Lab Invest Suppl. 2016;245:S113-8.
4. Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A, Wechalekar A, Berk J, Quarta C, Grogan M, Lachmann H, Bokhari S, Castano A, Dorbala S, Johnson G, Glaudemans A, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti P, Flatman K, Vonberg F, Whelan C, Ruberg F, Miller E, Hutt D, Hazenberg B, Rapezzi C, Hawkins P. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016. 14;133(24):2404-12.
5. Palladini G, Milani P, Foli A, Bassett M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, Lavatelli F, Barassi A, Albertini R, Merlini G. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clin Chem Lab Med 2016. 1;54(6):939-45.
6. Milani P, Valentini V, Ferraro G, Bassett M, Russo F, Foli A, Palladini G, Merlini G. A patient with AL amyloidosis with negative free light chain results. Clin Chem Lab Med. 2016. 1;54(6):1035-7.

7. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. *Expert Rev Cardiovasc Ther.* 2015 Nov; 13(11):1195-211.
8. Caccialanza R, Palladini G, Cereda E, Bonardi C, Milani P, Cameletti B, Quarleri L, Cappello S, Foli A, Lavatelli F, Klersy C, Merlini G. Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. *Nutrition.* 2015;31(10):1228-34.
9. Palladini G, Sachchithanathan S, Milani P, Gillmore J, Foli A, Lachmann E, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood.* 2015;126(5):612-5.
10. Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G. A practical approach to the diagnosis of systemic amyloidoses. *Blood* 2015; 125(14):2239-44.
11. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G. Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: a matched case control study on 174 patients. *Leukemia* 2014; 28(12):2311-6.
12. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schoenland SO. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. *Blood* 2014; 124: 2325-2332.
13. Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, Foli A, Cappelli F, Perfetto F, Palladini G, Rapezzi C, Merlini G. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. *J Hypertens* 2014; 32: 1121-1131.
14. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, Caccialanza R, Perlini S, Merlini G. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica* 2014; 99: 743-750.
15. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G. Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. *JPN J Parenter Enteral Nutr* 2014; 38: 891-894.
16. Wechalekar AD, Schoenland S, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Roard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 Patients with Stage III AL amyloidosis. *Blood* 2013; 121(17):3420-7.
17. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica* 2013; 98: 433-436.
18. Palladini G, Foli A, Milani P, Russo P, Albertini L, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *Am J Hematol* 2012; 87: 465-471.
19. Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, Lavatelli F, Sarais G, Casarini S, Moratti R, Melzi D'Eril GV, Merlini G. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid*, 2011 Dec;18(4) 216-21.
20. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G. Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis. *Ann Hematol* 2012 Mar; 91(3):399-406.
21. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide. *Ann Hematol* 2012 Jan; 91(1):89-92.
22. Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid* 2011; 18 Suppl 1: 87-88.
23. Palladini G, Foli A, Russo P, Milani P, Obici L, Lavatelli F, Merlini G. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone. *Clin Lymphoma Myeloma Leuk* 2011; 11: 143-145.
24. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Zenone Bragotti L, Obici L, Moratti R, Melzi d'Eril GV, Merlini G. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. *Blood* 2010; 116: 3426-30.

h-index (Web of Science): 10.


Pavia, 21 ottobre 2016